Forecast for the Nutraceuticals Industry: A Glimpse into 2024-2025

We sought insights from industry experts deeply versed in marketplace dynamics to discuss significant trends and developments in business, regulation, science, and the market that the industry should focus on in the upcoming year. Their insights span a range of issues, including state regulations, global supply chain strategies, women’s health, and more.

Michael McGuffin, President of the American Herbal Products Association (AHPA), highlighted the external pressures on the industry from both state and federal critics who often confuse lawful, safe dietary supplements with illegal products. He emphasized the importance of industry unity to capitalize on the opportunities that the new government might offer, particularly in distinguishing dietary supplements from other products. AHPA plans to promote new legislative language to empower the FDA to crack down on illegal products disguised as dietary supplements, enhancing consumer protection and industry integrity.

The industry faces challenges, including state efforts to limit access to dietary supplements, potentially invigorated by changes in federal power. The differentiation of legitimate supplements, addressing illegal products, and countering state restrictions are ongoing issues that will be crucial in 2025.

Duffy MacKay, Senior VP of Dietary Supplements at the Consumer Healthcare Products Association (CHPA), recalled the FDA’s 2010 warning about the public health risks of supplements containing active drug ingredients. This led to significant actions, including a 2015 investigation by the New York State Attorney General into fraudulent supplements, which spurred retailers to start their own screening processes, a phenomenon described as “regulation by retail.”

FDA continues to highlight the risks of contaminated supplements, with over 400 problematic products identified. Recent measures by Amazon, requiring third-party testing and certification for supplement sellers, represent a significant step towards safer consumer access to these products.

Steve Mister, President and CEO of the Council for Responsible Nutrition (CRN), discussed the Dietary Supplement Health and Education Act (DSHEA), which has been pivotal for the industry. He argued against sweeping changes to DSHEA, advocating instead for technical refinements to enhance FDA enforcement and align oversight with market growth. CRN aims to address specific regulatory challenges, like the drug preclusion clause, to foster innovation without compromising safety.

Karen Howard, CEO and Executive Director of the Organic & Natural Health Association, reviewed the association’s focus on regulatory integrity, market access, and scientific innovation. Efforts include improved testing methods, advocating for transparent labeling, and addressing the health needs of minority populations and women.

Loren Israelsen, President of the United Natural Products Alliance (UNPA), reflected on significant political and regulatory changes impacting the industry, including potential shifts in FDA policy and state-level reactions to federal policies.

Jim Emme, CEO of NOW Health Group, noted the company’s growth and ongoing challenges with supply chain and regulatory environments. He highlighted the impact of state laws, like New York’s restrictions on weight loss products, on consumer choice.

Karen E. Todd, VP of Global Brand Marketing at Kyowa Hakko USA, emphasized the consumer shift towards scientifically supported branded ingredients, noting the increasing demand for transparency and quality in supplements.

Shaheen Majeed, Global CEO & Managing Director of Sabinsa Corporation, discussed the importance of pesticide testing, promoting diversity in clinical research, and proactive supply chain management to address global uncertainties.

These insights collectively underscore the dynamic challenges and opportunities facing the dietary supplement industry as it navigates regulatory landscapes, market demands, and consumer safety concerns.